K2 HealthVentures’ Post

Did you know that a recent survey shows that roughly a third of Medicare patients (both Traditional and Medicare Advantage) struggle to access primary care? We are proud to support HarmonyCares, a leading provider of value-based, in-home longitudinal care. This capital raise will help expand their footprint and develop new technology to drive clinical outcomes and patient satisfaction at scale.

This week Life Science Cares Boston launched a Health Equity Portfolio Co-Investment Program as part of its Anti-Poverty Strategy for Greater Boston. We are proud that our foundation is able to support LSC’s new grantmaking program aimed at addressing health inequities among low-income families and communities in the area. Learn more: https://bit.ly/4aMDXnJ #lifesciences #giveback #antipoverty

Earlier this week K2HV attended Life Science Cares Boston’s Impact Breakfast & was awarded the Luke Timmerman Impact Award. Our team is honored to have received this recognition. In Parag Shah’s words, “We are up here being recognized because we notice the inequities that are out there, and we are fortunate to be able to give from our abundance, to give a little bit back.” As an anchor investor in Life Science Cares’ new Health Equity initiative, we are grateful to all those joining in our efforts to improve health equity & thank you Luke Timmerman for the honor. 

As we enter 2024, our team would like to reflect on K2HV’s progress and accomplishments. Learn more in our Year End Letter:

Today we are thrilled to announce our partnership with new portfolio company Acumen Pharmaceuticals, Inc., a clinical-stage drug development company focused on developing a novel therapeutic for #AlzheimersDisease, including ACU193, an investigational humanized monoclonal antibody that selectively targets toxic soluble amyloid-beta oligomers (AβOs). This $50M loan agreement will provide additional operational flexibility and will help fund, among other activities, Acumen’s development program for a subcutaneous form of ACU193.   Our collaboration further demonstrates K2HV’s ability to finance life sciences companies through multiple stages of development, and we look forward to supporting Acumen’s leadership team in realizing their mission of creating a potential best-in-class treatment for Alzheimer’s Disease.   Read more: https://k2hv.com/news

Today we are thrilled to partner with new portfolio company MindMed on a $50M credit facility to advance their portfolio of product candidates across an array of disorders of the brain where there are significant unmet medical needs. With $15M drawn at loan closing, this financing enhances MindMed’s operational and strategic flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates.   K2HV’s investment in MindMed further demonstrates our ability to finance life sciences companies through multiple stages of development and in emerging areas of the drug development ecosystem that hold great promise for patients. Read more: bit.ly/3qyHyVx

We’re #hiring a new Finance and Accounting Manager in Boston, Massachusetts. Apply today or share this post with your network.